FENNEC PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND THIRD QUARTER ENDED SEPTEMBER 30, 2014 FINANCIAL RESULTS

RESEARCH TRIANGLE PARK, NORTH CAROLINA–(Marketwired – Nov. 13, 2014) – • SIOPEL 6 Has Enrolled 112 Patients With Study Completion Expected by Year End • Safety Data on 100 Patients Expected During Q1 2015 • Name Change, Warrant Exchange and Share Consolidation Completed Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF) today reported its financial results and recent developments […]

FENNEC PHARMACEUTICALS ANNOUNCES OVER THE COUNTER TRADING SYMBOL CHANGE

RESEARCH TRIANGLE PARK, NC, Sept. 5, 2014 – Fennec Pharmaceuticals Inc. (TSX: FRX; OTC: ADHXD) (the “Company”) formerly known as Adherex Technologies Inc., today announced that the Financial Industry Regulatory Authority (“FINRA”) has approved the Company’s corporate actions regarding its previously announced name change and share consolidation. As of open of business on September 5, […]

ADHEREX ANNOUNCES SHARE CONSOLIDATION, NAME CHANGE AND TRADING SYMBOL CHANGE

RESEARCH TRIANGLE PARK, NC, Sept. 3, 2014 – Adherex Technologies Inc. (TSX: AHX; OTC: ADHXF) (the “Company”) announced today that it gave effect to the consolidation of its outstanding share capital on the basis of one new security for every three outstanding securities (the “Consolidation”).  In addition, the Company filed a Notice of Alteration with […]

ADHEREX PROVIDES CORPORATE UPDATE AND SECOND QUARTER ENDED JUNE 30, 2014 FINANCIAL RESULTS

August 11, 2014 Research Triangle Park, NC, August 11, 2014 – – Adherex Technologies Inc. (TSX: AXH, OTCQB: ADHXF), today reported its financial results and recent developments for the second quarter ended June 30, 2014. All amounts are in US dollars unless otherwise specified. As reported during the second quarter, the results from two Phase […]

ADHEREX ANNOUNCES WARRANT EXCHANGE RESULTS AND NEW CAPITAL STRUCTURE

Research Triangle Park, NC, August 8, 2014 – – Adherex Technologies Inc. (TSX: AXH, OTCQB: ADHXF), today reported the final results of the Warrant exchange which concluded on July 29, 2014.  Approximately, 71% of all outstanding warrants originally issued by the Company on April 30, 2010 and 48% of all outstanding warrants issued on March 29, 2011 participated in the exchange. […]

ADHEREX ANNOUNCES RESULTS FROM TWO SODIUM THIOSULFATE PHASE 3 STUDIES PRESENTED AT THE 50TH AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) MEETING

  –COG STUDY ACCL0431 meets primary endpoint for prevention of cisplatin-induced hearing loss in children -SIOPEL 6 Data Monitoring Committee recommends continuation of study after safety review of 80 standard risk hepatoblastoma patients   Research Triangle Park, NC — June 2, 2014 – Adherex Technologies, Inc. (TSX: AHX, OTC: ADHXF) today announced the results on the […]

Adherex Announces Results of Annual and Special Meeting

Research Triangle Park, NC — (Marketwire) – May 30, 2014 – Adherex Technologies Inc. (TSX:AHX, OTC: ADHXF) today announced that the nominees listed in the management proxy circular dated April 28,2014 (the “Circular”) for the Annual and Special Meeting of Shareholders were elected as directors of the Company at the Annual and Special Meeting of […]

Adherex Responds to Trading Activity

Research Triangle Park, NC — (Marketwire) – May 27, 2014 – Adherex Technologies Inc. (TSX:AHX, OTC: ADHXF) is responding to a request from the Investment Industry Regulatory Organization of Canada on behalf of the Toronto Stock Exchange following recent trading activity. Ordinarily, the Company’s policy is not to comment on rumors or speculation.  Adherex is […]

ADHEREX PROVIDES CORPORATE UPDATE AND FIRST QUARTER ENDED MARCH 31, 2014 FINANCIAL RESULTS

  Research Triangle Park, NC, May 15, 2014 – – Adherex Technologies Inc. (TSX: AXH, OTCQB: ADHXF), today reported its financial results and recent developments for the first quarter ended March 31, 2014. All amounts are in US dollars unless otherwise specified. As reported, the two Phase 3 clinical trials studying Sodium Thiosulfate (STS) for […]

Adherex Appoints Two Independent Directors

RESEARCH TRIANGLE PARK, NORTH CAROLINA — (Marketwire) – April 28, 2014 – Adherex Technologies, Inc. (TSX:AHX, OTC: ADHXF) today announced the appointment of Dr. Khalid Islam and Adrian Haigh to the Company’s Board of Directors, effective immediately.  With these additions, the Adherex Board is now comprised of five directors, four of whom are independent. “We welcome […]

Adherex Announces Two Sodium Thiosulfate Presentations for Prevention of Ototoxicity in Children at Asco Meeting

– COG STUDY ACCL0431 oral presentation for hearing protection in rare childhood cancers – SIOPEL 6 poster presentation for hearing protection in standard risk hepatoblastoma RESEARCH TRIANGLE PARK, NORTH CAROLINA–(Marketwire) – April 22, 2014) – Adherex Technologies, Inc. (TSX:AHX, OTC: ADHXF) today announced that both of the Phase III studies being conducted on Sodium Thiosulfate (STS) […]

Adherex Provides Corporate Update and Fiscal Year Ended December 31, 2013 Financial Results

RESEARCH TRIANGLE PARK, NORTH CAROLINA–(Marketwired – Mar 31, 2014) – Adherex Technologies Inc. (AHX.TO)(ADHXF), today reported its financial results and recent developments for the year ended December 31, 2013. All amounts are in US dollars unless otherwise specified. The two Phase 3 clinical trials studying Sodium Thiosulfate (STS) for prevention of hearing loss in children receiving […]

Adherex Announces Sodium Thiosulfate Clinical Study Update

RESEARCH TRIANGLE PARK, NORTH CAROLINA–(Marketwired – Feb 27, 2014) – Adherex Technologies, Inc. (AHX.TO)(ADHXF) today announced that the Children’s Oncology Group (COG), posted top line results on http://clinicaltrials.gov/ under Study ACCL0431, A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children. No statistical analysis was published and a full analysis of all […]